For the treatment of patients with advanced or metastatic non-small cell lung cancer who progressed on or after platinum-based chemotherapy in combination with docetaxel
Dossier fermé – Non présenté
Pre Noc Submission:
Date NOC Issued:
Eli Lilly Canada Inc.
The submitter notified pCODR that they will not be filing the submission.
The submitter notified pCODR that they were unable to submit by their original target date and an updated target submission date has been provided.
‡ Patient Advocacy Groups (or individual patients and caregivers
when there is no patient group) and Clinicians who are registered
with pCODR are eligible to provide Input and Feedback.
Deadlines for Input and Feedback are by the end of the pCODR business day
(5P.M. Eastern Time) of the date noted.